PCN29 HRQOL DURING ADJUVANT CHEMOTHERAPY WITH CAPECITABINE IN PATIENTS AFTER SURGERY FOR COLON CANCER: ADDITIONAL STUDY OF JFMC37-0801
Tokyo Medical and Dental University, Graduate School, Tokyo, Japan, 2 Ritsumeikan University, Kusatsu, Shiga, Japan, 3 National Institute of Public Health, Saitama, Japan, 4 Hyogo College of Medicine, Hyogo, Japan OBJECTIVES: The JFMC37-0801 trial is a phase III trial designed to validate superiority of 1-year treatment with capecitabine to 6 months treatment as adjuvant chemotherapy for stage III colon cancer. Health related quality of life (HRQOL) and cost-effectiveness have been evaluated as an additional study. We analyzed impact of prolonged treatment with capecitabine on patients' HRQOL. METHODS: Capecitabine (2500mg/m 2 /day) was orally given on days 1-14, followed by a 7-day rest. Enrolled patients were randomly assigned to group A (received 8 courses of capecitabine) or group B (16 courses). In patients agreed to participate to the additional study, HRQOL was evaluated by self-administered questionnaire at the start of the protocol treatment, 3, 6, 9, 12, 15 and 18 months. The questionnaire includes Functional Assessment of Cancer therapy-C (FACT-C) and EuroQol 5 Dimension (EQ-5D). RESULTS: In 1306 patients enrolled to the JFMC37-0801 trial, HRQOL of 171 participants (81 in group A, 90 in group B) were evaluated. Mean age of the patients in group A and B was 63.3 and 64.5 years-old, respectively. Among a total of 1197 points of survey, 959 questionnaires (80.1%) were retrieved. Recovery rates of questionnaires tended to decrease with time after finishing treatment. Through the entire survey period, mean score of FACT-C (96.9-103) and EQ-5D (0.85-0.93) were satisfactory. In longitudinal analysis of the change from baseline score, the scores tended to increase after finishing the treatment period in both group A and group B. Significant difference between the score of group A and group B was not observed in each survey point. No difference by age and tumor stage was also observed. CONCLUSIONS: HRQOL of the patients received postoperative adjuvant chemotherapy with capecitabine was satisfactory through the survey period. There was no significant difference of HRQOL between 8 and 16 courses of capecitabine treatment. (60/75, pϭ0.01) , aged between 38 and 57 (44/75), and were from Malay ethnicity (46/75). Socio-demographic factors including age (rϭ0.15, pϭ0.03) and monthly house hold income (rϭ -0.25, pϽ0.001) were strongly correlated with MBCTs use. Prayers for health reasons was the highest 51 (27.7%), followed by spiritual practices 20(10.8%), meditation 7(5.9%), tai chi 7(3.8%), music therapy 4(2.1%), Qigong 1(0.5%), hypnotherapy 1(0.5%), and reiki 1(0.5%). Recommendations from friends and family members 53(70%) were the most common reasons of MBCTs use followed by patient's own will 22(29.3%). Health related Quality of Life (HRQoL) scores shows significant difference in functional and symptoms scores among MBCTs users and non-users. CONCLUSIONS: Nearly half of the CAM users utilized some types of MBCTs. Prayers specifically for health reasons and spiritual practices are somewhat common among cancer patients. Viewing MBCTs not as alternative but to complement cancer therapies to address emotional and psychological needs may help in improving health related quality of life (HRQoL) of cancer patients. 
PCN30 USE OF MIND BODY COMPLEMENTARY THERAPIES (MBCTS) AMONG MALAYSIAN ONCOLOGY PATIENTS

PCN31 A CROSS-SECTIONAL ASSESSMENT OF THE QUALITY OF LIFE OF CANCER PATIENTS AND THEIR COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) USE
OBJECTIVES:
To examine the prevalence of CAM use among Malaysian cancer patients and compare the differences in health-related quality of life (HRQoL) between CAM users and non-users. METHODS: This cross-sectional study was undertaken with 393 patients at the oncology wards of Penang General Hospital, Malaysia. The HRQoL between CAM users and non-users was assessed by using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). RESULTS: The majority (46.1%) of the participants were frequent CAM users. The most common CAM therapies were dietary and nutritional supplements (41.3%), herbal products (30.4%), prayers for health reasons including spirituality (22.8%), traditional Malay therapies (20.11%) and Traditional Chinese Medicines (14.1%). No significant difference was found between functional and symptoms scores among CAM users and non-users. However; global health scores/quality of life was significantly different (Pϭ0.002) between CAM users and non-users. CONCLUSIONS: Patients' interest in the use of CAM highlights the need of greater health care education in this field. This study provides evidence of CAM use and its overall effects on quality of life scores in a sample of patients with cancer. Patients should be aware of the potential benefits of CAM therapies for cancer. Health care professionals can play their role effectively to encourage patients towards rational use of CAM therapies. 
PCN32 QUALITY OF LIFE OF CANCER PATIENTS RECEIVING CAPECITABINE MONOTHERAPY AT NAKHON PATHOM HOSPITAL NAKHON PATHOM HOSPITAL
OBJECTIVES:
To assess quality of Life (QoL) among cancer patients receiving capecitabine at Nakhon Pathom Hospital in Thailand. METHODS: Cancer patients receiving capecitabine, either as monotherapy or in combination with other anticancer drugs, at Nakhon Pathom Hospital, were recruited during July to September 2011. The Thai version of the Functional Assessment of Cancer Therapy-General (FACT-G) comprising four subscales, physical well-being (PWB), social/family wellbeing (SWB), emotional well-being (EWB) and functional well-being (FWB), was utilized to assess QoL of these patients. Demographic data (age, gender,status, educational level, occupation, and monthly income) as well as medical history (type, stage and duration of cancer) of the patients were also collected. RESULTS: Altogether 13 patients receiving capecitabine monotherapy and 24 patients receiving capecitabine combination therapy were recruited in this study. Their mean (SD) overall QoL score was 51.66 (9.33) from 108 . While the mean (SD) scores for PWB, SWB, EWB and FWB subscales were 8.60 (5.86), 19.91 (5.75) from 28, 7.38 (4.96) from 24 and 15.77 (7.88) from 28, respectively. The mean QoL in this group of patients were lower than normaltive data. Only subscal SBW that higher than normative data. The score of BEWϽPWBϽFWBϽSWB. No significant relationship was revealed between demographic data and any subscales of the FACT-G in patients receiving capecitabine monotherapy, CONCLUSIONS: The QoL in patients who receive capecitabine monotherapy are lower than normative data. Even though , no relationships are found between demographic data and any subscales. The activities to improve patients' emotion should be establish to improve quality of life of the patients.
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